Online inquiry

IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13601MR)

This product GTTS-WQ13601MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13601MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8286MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ15120MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ8212MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ1990MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ5327MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ10538MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ2697MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ1744MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW